Released: 27/04/2018 – 17:09 GMT
RNS Number: 4637M
27 April 2018
Castelvecchio Pascoli (Lucca, Italy), 27 April 2018 – The Annual General Meeting of Shareholders of Kedrion S.p.A., a biopharmaceutical company that specializes in the development, production and distribution of plasma‐derived therapies and in the collection of plasma, has approved today the individual financial statements of the Company for the year ended 31 December 2017 and has acknowledged its 2017 consolidated financial statements.
The Meeting then confirmed the Board of Directors by reappointing the following 7 directors: Paolo Marcucci, as Chairman, and Maria Lina Marcucci, Andrea Marcucci, Rodolfo De Dominicis, Remo Grassi, Umberto Della Sala and Guido Rivolta.
The Meeting also appointed to the Board of Statutory Auditors Fabrizio Redaelli, as Chairman, and Francesco Cirillo and Marco Miccinesi, as permanent auditors. Alessandro Bicchi and Giuseppe Paternò were appointed as alternate auditors.
At the conclusion of the Shareholders’ Meeting, the Board of Directors met and confirmed Paolo Marcucci as Chief Executive Officer.
For further information, please write to [email protected]
Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.
The Company operates through a fully integrated business model from the collection of plasma in its own centers in the United States, Hungary and Germany to fractionation and production in its manufacturing facilities located in Italy, Hungary and the United States.
Headquartered in Castelvecchio Pascoli (Italy), Kedrion has over 2,400 employees and a commercial presence in approximately 100 countries worldwide.
Kedrion places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves.
Additional information about Kedrion can be found at kedrion.com
This document contains forward-looking statements on overall economic development as well as on the business and assets position of Kedrion S.p.A. and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Kedrion does not intend to update the forward-looking statements and assumes no obligation to do so.